LONDON, April 7 /PRNewswire/ --
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received marketing authorisation for piperacillin/tazobactam for injection, and has launched the product in the United Kingdom. The medication is a generic version of Wyeth's Tazocin(R), the world's leading injectable antibiotic, with 2008 European sales of approximately 250 million euros.(1)
Piperacillin/tazobactam is a broad-spectrum antibiotic used to treat patients with moderate to severe infections. It is an injectable combination product that consists of piperacillin (an extended-spectrum penicillin) and tazobactam (a beta-lactamase inhibitor).